Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

51% of Americans disapprove of Trump's migrant ban

Giuseppe Milo / Flickr Creative Commons

CBS's new poll showed America just about split over Trump and some of his first key actions. As usual, the divide falls mostly along party lines.

Refugee ban: More people disapprove than approve of Trump's ban — 51% to 45%. And 57% think the temporary ban is against the nation's founding principles. However, most Republicans think it makes America safer.

SCOTUS Nominee: While 56% can't decide yet, more Americans think the Senate should confirm Gorsuch, than think they should vote against him.

Trump himself: 40% of Americans approve of Trump's work so far — the lowest approval rating of any president at this point in the presidency.

Go deeper

Dave Lawler, author of World
10 mins ago - World

Latin America turns to China and Russia for COVID-19 vaccines

A healthcare worker prepares a Sinovac Biotech Ltd. Covid-19 vaccine in Sao Paulo, Brazil. Photo: Jonne Roriz/Bloomberg via Getty Images

Several countries in the Americas have received their first vaccine shipments over the past few weeks — not from the regional superpower or from Western pharmaceutical giants, but from China, Russia, and in some cases India.

Why it matters: North and South America have been battered by the pandemic and recorded several of the world’s highest death tolls. Few countries other than the U.S. have the capacity to manufacture vaccines at scale, and most lack the resources to buy their way to the front of the line for imports. That’s led to a scramble for whatever supply is available.

Go deeper (2 min. read)Arrow
Marisa Fernandez
58 mins ago - Health

More schools are reopening in the U.S.

Students settle into a classroom in New York City. Photo: Michael Loccisano/Getty Images

More than 72% of K-12 students are now attending schools that offer in-person or hybrid models of learning.

The big picture: The U.S. is seeing an almost-universal return of schools that were in-person as of November, as well as a gradual return in parts of the country that had been virtual for almost a year.

Go deeper (1 min. read)Arrow
Courtenay Brown
1 hour ago - Economy & Business

The manufacturing boom's bottleneck

llustration: Rebecca Zisser/Axios

The manufacturing sector has bounced back from its pandemic knockout. But as the economy reopens, factories can't keep up with orders.

Why it matters: The materials manufacturers need are hard to find and prices for them are soaring.

Go deeper (1 min. read)Arrow